Sitemap

Pages

• Adoptive T-cell therapy targeting Epstein–Barr virus as a treatment for multiple sclerosis
• Terms of Use
• Expanded Access
• Clinical Studies
• Multiple Sclerosis
• PTLD
• About EBV
• Patients & Families
• Contact
• Stories of Strength
• Careers
  • Career Areas
• PO Terms and Conditions
• Suppliers
• Job Search
• Independent Medical Education
• Expanded Access
• Clinical Studies
• Job Categories
• Medical Professionals
  • Request Information
• Pipeline
  • ATA3431
  • ATA188
  • ATA3219
  • Tab-cel
• Technology
  • Next Generation CAR T
  • Manufacturing
• Privacy Policy
• About Us
  • Responsibility
  • Collaborators
  • Board of Directors
• Atara Biotherapeutics

MS Stories

• Mitch, MS Advocate
• Dan, MS Advocate

PTLD Stories

• Ola: Heart and kidney transplant, PTLD Advocate
• Ayden: Kidney transplant, PTLD Advocate
• Allison: Double lung transplant, PTLD Advocate
• Swapna: Small intestine transplant, PTLD Advocate

Publications

• ATA3219: Allogeneic CD19 CAR EBV T Cells for the Treatment of B-Cell Driven Autoimmune Diseases
• ATA3431: Allogeneic CD19/CD20 Bispecific CAR EBV T-cells for the Treatment of B-Cell Malignancies
• Optimization and Characterization of ATA3219: A Novel and Potent Allogeneic CD19-CAR T Therapy Without Gene Editing
• Phase 1 Study of the Safety and Efficacy of ATA188, an Off-the-shelf, Allogeneic Epstein-Barr Virus-targeted T-cell Immunotherapy to Treat Progressive Forms of Multiple Sclerosis
• Functional Demonstration of CD19 Chimeric Antigen Receptor (CAR) Engineered Epstein-Barr Virus (EBV) Specific T Cells: An Off-the-Shelf, Allogeneic CAR T-Cell Immunotherapy Platform